NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement.
Extracellular factors control the angiogenic switch in endothelial cells (ECs) via competing survival and apoptotic pathways. Previously, we showed that proangiogenic and antiangiogenic factors target the same signaling molecules, which thereby become pivots of angiogenic balance. Here we show that in remodeling endothelium (ECs and EC precursors) natural angiogenic inhibitors enhance nuclear factor-kappaB (NF-kappaB) DNA binding, which is critical for antiangiogenesis, and that blocking the NF-kappaB pathway abolishes multiple antiangiogenic events in vitro and in vivo. NF-kappaB induction by antiangiogenic molecules has a dual effect on transcription. NF-kappaB acts as an activator of proapoptotic FasL and as a repressor of prosurvival cFLIP. On the FasL promoter, NF-kappaB increases the recruitment of HAT p300 and acetylated histones H3 and H4. Conversely, on cFLIP promoter, NF-kappaB increases histone deacetylase 1 (HDAC1), decreases p300 and histone acetylation, and reduces the recruitment of NFAT, a transcription factor critical for cFLIP expression. Finally, we found a biphasic effect, when HDAC inhibitors (HDACi) were used to test the dependence of pigment epithelial-derived factor activity on histone acetylation. The cooperative effect seen at low doses switches to antagonistic as the concentrations increase. Our study defines an interactive transcriptional network underlying angiogenic balance and points to HDACi as tools to manipulate the angiogenic switch.
Aurora
Arin B
AB
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Aurora
Aryn B
AB
Biyashev
Dauren
D
Mirochnik
Yelena
Y
Zaichuk
Tetiana A
TA
Sánchez-Martinez
Cristina
C
Renault
Marie-Ange
MA
Losordo
Douglas
D
Volpert
Olga V
OV
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000235:genetics; D042002:Chromatin Assembly and Disassembly / Q000502:physiology*; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D005136:Eye Proteins / Q000494:pharmacology; D053222:Fas Ligand Protein / Q000235:genetics / Q000378:metabolism; D005260:Female; D056284:Histone Deacetylase 1 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D016328:NF-kappa B / Q000502:physiology*; D050778:NFATC Transcription Factors / Q000235:genetics / Q000502:physiology*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000235:genetics; D009414:Nerve Growth Factors / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D015843:Serpins / Q000494:pharmacology; D015398:Signal Transduction; D019700:Thrombospondin 1 / Q000494:pharmacology; D000099174:Pigment Epithelium-Derived Factor
D020533:Angiogenesis Inhibitors; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D005136:Eye Proteins; D053222:Fas Ligand Protein; D056284:Histone Deacetylase 1; D016328:NF-kappa B; D050778:NFATC Transcription Factors; D009414:Nerve Growth Factors; D015843:Serpins; D019700:Thrombospondin 1; D000099174:Pigment Epithelium-Derived Factor; C506387:Cflar protein, mouse; C505658:Fasl protein, mouse; C494007:Nfatc2 protein, mouse; C484389:Hdac1 protein, mouse